alpha-aminopyridine has been researched along with Cystadenocarcinoma, Serous in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Eismann, J; Gray, KP; Heng, YJ; Konstantinopoulos, PA; Matulonis, UA; Murphy, CJ; Nabavi, S; Vlachos, IS; Waldschmidt, JM; Wulf, GM | 1 |
1 other study(ies) available for alpha-aminopyridine and Cystadenocarcinoma, Serous
Article | Year |
---|---|
Transcriptome analysis reveals overlap in fusion genes in a phase I clinical cohort of TNBC and HGSOC patients treated with buparlisib and olaparib.
Topics: Adult; Aged; Aminopyridines; Antineoplastic Combined Chemotherapy Protocols; Clinical Trials, Phase I as Topic; Cystadenocarcinoma, Serous; Female; Forkhead Transcription Factors; Gene Expression Profiling; Gene Fusion; Humans; Middle Aged; Morpholines; Ovarian Neoplasms; Phthalazines; Piperazines; Repressor Proteins; RNA-Seq; Triple Negative Breast Neoplasms | 2020 |